Market Overview

UBS Says Pfizer Has 'Underappreciated' Oncology Portfolio After ASCO


In a report published Wednesday, UBS analyst Marc Goodman maintained a Buy rating on Pfizer Inc (NYSE: PFE), with a price target of $39.

Pfizer management indicated that Ibrance has captured a 20 percent market share in a very short time. The company also highlighted some other programs that could significantly expand its commercial opportunities.

Pfizer is well positioned to be a credible player in the next wave of IO combo therapies with its NCEs and appears to have a good lead in mono for 4-1BB and a combo of 4-1BB is in Phase I.

In the report UBS noted that the company's shares did not move much after the ASCO as the markets had alredy anticipated the Ibrance information.

"The street underappreciates Pfizer's oncology franchise, including Ibrance, second wave IO combos, as well as the rest of the earlier stage technologies, which we think in addition to expected additional acquisitions should support solid growth in the innovative bizz," analyst Marc Goodman mentioned.

Latest Ratings for PFE

Jun 2020JP MorganMaintainsNeutral
Apr 2020BarclaysMaintainsEqual-Weight
Apr 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Posted-In: UBSAnalyst Color Reiteration Analyst Ratings

Latest Ratings

FORMSidoti & Co.Maintains32.0
BHESidoti & Co.Maintains28.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at